Effect of liposomal doxorubicin enhanced DVD regimen on multiple myeloma / 肿瘤研究与临床

ABSTRACT

Objective To explore the efficacy and feasibility of additional liposome doxorubicin with DVD regimen in the treatment of multiple myeloma (MM). Methods Thirty patients with MM in Chinese PLA General Hospital from January 2012 to January 2015 were selected and divided into treatment group (DVD group,liposomal doxorubicin+vincristine+dexamethasone),control group A(VTD group,bortezomib+thalidomide+dexamethasone) and control group B (VAD group, pirarubicin+vindesine+dexamethasone) with 10 cases in each,including 18 males and 12 females,aged from 36 to 72 years old,and the mean age was 55.8 years. The treatment effect and adverse reactions among the three groups were compared. Survival analysis was evaluated through Kaplan-Meier and Log-rank tests. Results Followed up to January 31st 2016, the therapy related mortality rates in three groups were 10%(1/10), 20%(2/10) and 10%(1/10), the total efficiency rates were 80%(8/10), 100%(10/10) and 60%(6/10), the median survival time was 25.5, 25.2 and 21.6 months, the disease free survival rates were 70%(7/10), 80%(8/10) and 50%(5/10). Survival analysis showed that the difference between DVD and VTD group was not significant (P=0.098) and there were significant differences between DVD and VAD group(P=0.027),VTD and VAD group(P=0.012). The incidence of peripheral neurotoxicity in VTD group(70%,7/10)was higher than that in other two group(χ2=14.7,P=0.007), and there was no significant difference in the other adverse reactions among the three group (all P>0.05). Conclusions In the treatment of MM, the efficacy of liposomal doxorubicin enhanced DVD regimen is similar to the VTD regimen and more effective than the traditional VAD regimen. It is a safe and effective method for MM.